Rocket Pharmaceuticals said Tuesday that a patient had died in a trial studying its experimental gene therapy for a rare heart condition called Danon disease.

Rocket did not disclose the patient’s age, although the Phase 2 study aimed to enroll boys and young men. The company said it was still investigating the cause of the death.

It suspects a drug given to suppress patients’ immune systems before receiving the gene therapy may have played a role.